Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its class—Eli Lilly’s Verz | It’s been seven years since Pfizer scored an expansion for its blockbuster Ibrance. But it finally happened Wednesday with a nod as a maintenance therapy in HR+/HER2+ breast cancer.